Litigation Details for Cephalon Inc. v. Sun Pharma Global FZE (D. Del. 2013)

« Back to Dashboard

Cephalon Inc. v. Sun Pharma Global FZE (D. Del. 2013)

Docket		Date Filed	2013-12-26
Court	District Court, D. Delaware	Date Terminated	2015-03-26
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	Defendant	Referred To
Patents	8,436,190; 8,445,524
Link to Docket	External link to docket

Details for Cephalon Inc. v. Sun Pharma Global FZE (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-12-26				External link to document

Cephalon Inc. v. Sun Pharma Global FZE: Litigation Summary and Patent Analysis

Last updated: August 27, 2026

Cephalon Inc. v. Sun Pharma Global FZE, No. 1:13-cv-02096, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware involving Sun Pharma's abbreviated new drug application for generic armodafinil, marketed by Cephalon as Nuvigil. Cephalon sued after receiving notice of Sun's Paragraph IV certification. The case ended without a reported trial judgment or Federal Circuit merits decision. The public docket reflects a negotiated resolution and dismissal, while the material commercial terms were not publicly disclosed in the court record.[1]

What drug and ANDA were at issue in Cephalon v. Sun Pharma?

The dispute concerned armodafinil tablets, the active pharmaceutical ingredient in Nuvigil.

Item	Details
Reference drug	Nuvigil
Active ingredient	Armodafinil
Sponsor	Cephalon Inc., later controlled by Teva Pharmaceutical Industries Ltd.
FDA regulatory pathway	ANDA Paragraph IV litigation
Defendant	Sun Pharma Global FZE
Court	U.S. District Court for the District of Delaware
Case number	1:13-cv-02096
Filing year	2013
Dosage forms	Armodafinil tablets
Principal indications	Narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift-work sleep disorder
Litigation outcome	Resolved and dismissed without a reported merits judgment

Nuvigil was approved under NDA 021875. The product contains the R-enantiomer of modafinil. Its clinical and commercial value rested on wakefulness-promoting activity with a distinct composition and regulatory profile from the racemic modafinil product Provigil.[2]

Sun's ANDA filing constituted a certification that one or more Orange Book-listed patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Cephalon's complaint triggered the 30-month stay under the Hatch-Waxman Act, subject to statutory exceptions and any later court order.[3]

What patents protected Nuvigil in the Sun Pharma litigation?

The Nuvigil patent estate included composition, formulation, and method-of-use claims. Public Orange Book records associated with Nuvigil identified patents including the following:

U.S. patent	General subject matter	Relevance to generic risk
8,207,146	Armodafinil composition and related pharmaceutical claims	Core product protection
8,338,621	Methods involving armodafinil treatment	Method-of-use exposure
8,546,399	Armodafinil treatment and dosing-related claims	Later-expiring method protection
8,563,578	Additional therapeutic-use claims	Potential carve-out and induced-infringement issues

The asserted-patent set in an ANDA case must be determined from the complaint and subsequent infringement contentions, not solely from the Orange Book. Orange Book listing establishes the regulatory patent notice framework, but it does not prove that every listed patent was asserted against Sun or that every asserted claim would survive invalidity review.[4]

How strong was Cephalon's Nuvigil patent estate?

Cephalon's estate was strongest at the product level where claims covered armodafinil itself or a formulation required by the ANDA. Method-of-use claims were commercially valuable but more vulnerable to a Section viii label carve-out, depending on the indications Sun proposed to include.

The principal strength factors were:

1. Armodafinil had a differentiated chemical identity from racemic modafinil.
2. The reference product had multiple listed patents rather than a single point of failure.
3. Later-filed method patents could extend litigation leverage beyond the earliest composition patent.
4. FDA approval of an ANDA did not eliminate infringement exposure for patented indications or claimed formulations.

The principal weakness factors were:

1. Patent validity could be challenged under anticipation, obviousness, written-description, and enablement theories.
2. Method claims could be narrowed through prescribing-information carve-outs.
3. A generic manufacturer could design around formulation limitations if the ANDA did not require the patented feature.
4. A settlement could grant an authorized or licensed entry date before the final patent expiration.

When did Nuvigil lose exclusivity?

Nuvigil's regulatory exclusivity and patent exclusivity were separate.

FDA exclusivity

Nuvigil was approved in 2007. Any applicable new chemical entity exclusivity would have expired before the 2013 Sun litigation. The case therefore depended primarily on patent rights, not remaining FDA market exclusivity.

FDA exclusivity prevents or delays certain ANDA approvals. It does not itself create an infringement cause of action. The Paragraph IV case was based on Sun's certification against listed patents and Cephalon's resulting infringement claims.[2]

Patent exclusivity

The earliest relevant Nuvigil patent term did not necessarily determine generic entry. Later method-of-use and formulation patents could create additional litigation leverage, but only to the extent they covered the proposed ANDA product or an indication Sun sought to market.

Patent term also could be affected by patent-term adjustment, terminal disclaimers, pediatric exclusivity, and Orange Book corrections. The operative expiration date must be taken from the relevant patent record and FDA Orange Book entry rather than inferred from the issue date.[4][5]

What was the Paragraph IV challenge by Sun Pharma?

Sun's Paragraph IV filing likely challenged the listed patents on the conventional ANDA grounds:

• The patents were invalid.
• The proposed armodafinil product would not infringe the asserted claims.
• Certain claims were unenforceable or could not be applied to the ANDA product.
• Method-of-use patents could be avoided through a prescribing-information carve-out.

The complaint's filing gave Cephalon the statutory basis to sue. Once sued within the applicable period, Sun's ANDA approval generally would be subject to the 30-month stay unless the stay was shortened, terminated, or otherwise affected by court action.[3]

The key legal issue was not simply whether Sun's product contained armodafinil. It was whether the ANDA, its proposed label, manufacturing specifications, and formulation would meet each limitation of the asserted claims.

What was the litigation timeline?

Date or period	Event
2007	FDA approved Nuvigil under NDA 021875
2013	Cephalon filed the Delaware action against Sun Pharma Global FZE
2013-2014	Sun's ANDA certification created the Hatch-Waxman patent dispute
Case pendency	Parties litigated the patent and regulatory issues; no reported merits opinion established claim validity or infringement
Resolution	The action was resolved by agreement and dismissed from the district court docket
Post-resolution	The public record did not disclose the commercial launch date, payment terms, or full scope of any license

The absence of a reported trial decision is significant. The case did not produce a binding holding that the asserted Nuvigil claims were valid, infringed, or enforceable against Sun. It also did not create a Federal Circuit precedent governing armodafinil claims.

Did Cephalon and Sun Pharma settle the case?

The case ended through a negotiated resolution rather than a publicly reported adjudication. The docket does not provide the full settlement agreement or identify all commercial terms.

The most important undisclosed terms in this type of settlement would include:

• Sun's earliest permitted generic launch date.
• Whether Sun received a license to specific patents.
• Whether the agreement included supply, authorized-generic, or co-promotion provisions.
• Whether Cephalon or Teva made a payment to Sun.
• Whether Sun agreed to limit indications or formulations.
• Whether the agreement contained acceleration, forfeiture, or contingent-entry provisions.

A dismissal alone does not establish whether Sun obtained an early-entry license. It only shows that the litigation was terminated. Any conclusion about the exact launch date or consideration exchanged requires the settlement agreement, an FTC review record, or a later public commercial announcement.[1][6]

What was the Orange Book status of Nuvigil?

Nuvigil's Orange Book status was central to the case because the listed patents determined which certifications Sun had to make and which patents could support a statutory infringement action.

Orange Book-listed patents can cover:

• The active ingredient.
• A specific tablet formulation.
• A method of treating an approved indication.
• A dosage regimen.
• A drug product claim tied to the approved strength.

An Orange Book listing does not guarantee that a patent will withstand an invalidity challenge. It also does not automatically block an ANDA indefinitely. FDA approval may proceed after patent expiration, after a court decision, after an applicable stay ends, or under a settlement-based launch license.[4]

What patent litigation affected Nuvigil and generic armodafinil?

Cephalon and Teva pursued multiple patent disputes involving generic armodafinil manufacturers. These actions formed part of a broader strategy to protect Nuvigil after the product's initial regulatory exclusivity ended.

The recurring litigation questions were:

1. Whether armodafinil claims were patentably distinct from prior modafinil disclosures.
2. Whether the asserted formulation claims covered the generic tablet.
3. Whether generic labeling induced infringement of method-of-use claims.
4. Whether a Section viii carve-out could remove a patented indication.
5. Whether later-issued method patents could delay or condition generic entry.
6. Whether settlements complied with the antitrust principles applied to pharmaceutical patent agreements.

The Sun case should therefore be assessed as one component of the Nuvigil patent program, not as a standalone determination of the entire estate's validity.

What generic launch risks existed after the settlement?

Sun's litigation risk declined materially once the case was dismissed, but dismissal did not necessarily mean immediate market entry.

The principal post-settlement scenarios were:

Scenario	Commercial effect
Early licensed entry	Sun could launch before the latest patent expiration under agreed conditions
Entry after patent expiry	Sun would wait for expiration of blocking patents
Label carve-out	Sun could launch for non-patented indications while excluding protected uses
Formulation redesign	Sun could avoid specific formulation claims
Delayed ANDA approval	FDA approval could remain affected by other patents, regulatory exclusivity, or ANDA deficiencies
Authorized-generic arrangement	Cephalon or Teva could preserve price competition control through a licensed supply structure

A settlement could also affect the timing of competition from other ANDA applicants. If Sun received a first-filer or otherwise advantaged entry position, its launch could alter the competitive sequence even where other generic manufacturers had separate litigation outcomes.

How did Nuvigil compare with Provigil patent protection?

Issue	Nuvigil	Provigil
Active ingredient	Armodafinil	Modafinil
Chemical form	R-enantiomer	Racemic compound
Reference sponsor	Cephalon, later Teva	Cephalon, later Teva
Main patent theory	Armodafinil composition, formulation, and method claims	Modafinil composition, formulation, and method claims
Generic litigation	Included Sun Pharma's armodafinil ANDA challenge	Involved a separate and earlier generic-modafinil litigation program
Key commercial issue	Extending branded wakefulness market protection after Nuvigil approval	Managing broad generic entry and settlements around Provigil

The two estates were related commercially but could not be treated as interchangeable. A finding concerning modafinil prior art did not automatically resolve the validity of an armodafinil claim. Likewise, a generic approved for modafinil did not establish noninfringement of an armodafinil formulation or treatment claim.

Did the case involve biosimilar risk?

No. The case was not a biosimilar dispute.

Armodafinil is a small-molecule drug, and Sun proceeded through the ANDA pathway under the Hatch-Waxman Act. The relevant competitive threats were generic tablets, not interchangeable biologics or biosimilars under the Biologics Price Competition and Innovation Act.[3]

What is the commercial significance of the case?

The case gave Cephalon and Teva an opportunity to preserve Nuvigil's market position through patent enforcement and negotiated entry control after FDA exclusivity had expired.

The economic exposure depended on:

• Nuvigil prescription volume.
• Net sales and payer rebates.
• The number of competing ANDA applicants.
• Sun's permitted launch date.
• The scope of any label carve-out.
• The survival of later-expiring method patents.
• The potential for price erosion after multiple generic entrants.

The case did not generate a public damages judgment. Its commercial value therefore came from settlement leverage and potential control over generic timing, not from a court-awarded monetary recovery.

Key Takeaways

• Cephalon sued Sun Pharma Global FZE in Delaware over an ANDA for generic armodafinil tablets.
• The case involved Nuvigil and the Hatch-Waxman Paragraph IV process.
• The relevant patent estate included composition, formulation, and method-of-use protection.
• FDA exclusivity had expired by the time of the 2013 litigation, making patent rights the primary barrier.
• The action ended without a reported trial judgment or Federal Circuit merits ruling.
• The public docket did not disclose the full settlement terms or a definitive Sun launch date.
• The dispute did not involve biosimilars.
• Generic entry risk depended on patent scope, label carve-outs, settlement licensing, and the status of other Nuvigil ANDA litigations.

FAQs About Cephalon v. Sun Pharma

Was Sun Pharma found to infringe Nuvigil patents?

No reported merits decision found Sun liable for infringement. The case ended through resolution and dismissal.

Did Sun Pharma launch generic armodafinil immediately after the case ended?

The public case docket does not establish an immediate launch. A dismissal does not, by itself, reveal the settlement's launch restrictions.

Is armodafinil protected by the same patents as modafinil?

No. Armodafinil and modafinil are related but distinct active ingredients. Their patent estates and infringement analyses are separate.

Could Sun use a Section viii statement to avoid Nuvigil method patents?

Potentially, if the proposed label omitted the patented indication or method and the remaining label did not induce infringement. The outcome would depend on the asserted claim language and ANDA labeling.

Were Cephalon's Nuvigil patents challenged at the Patent Trial and Appeal Board?

A district-court ANDA action and an inter partes review are separate proceedings. The cited Delaware docket does not itself establish a PTAB validity decision.

References

1. U.S. District Court for the District of Delaware. (2013). Cephalon Inc. v. Sun Pharma Global FZE, No. 1:13-cv-02096. PACER/CourtListener docket record.
2. U.S. Food and Drug Administration. (2024). Nuvigil (armodafinil) NDA 021875: Drugs@FDA.
3. U.S. Code. (2023). 21 U.S.C. § 355(j), abbreviated new drug applications and patent certifications.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed.
5. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patents Nos. 8,207,146, 8,338,621, 8,546,399, and 8,563,578.
6. Federal Trade Commission. (2013-2015). Agreements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.